IMproving PAtient UndeRstanding of GEP TEst Results: Phase 4

Recruiting now · Not applicable

Conditions studied: Breast Cancer

In brief

The primary aim of the study is to determine if provision of a patient information film about Oncotype DX improves patients' knowledge and understanding about Gene Expression Profiling (GEP) test and risk of recurrence results in early breast cancer (EBC) patients, identified by their clinical teams as potentially benefiting from having their tumor samples sent for GEP analysis.

Key facts

Study ID

NCT06703567

Run by

European Institute of Oncology

People needed

82

Starts

2024-09-06

Expected to finish

2025-12-01

Last updated by the study team

2024-12-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• First presentation of early stage breast cancer with all known disease surgically removed
• Estrogen Receptor (ER) positive and Human Epidermal growth factor Receptor 2 (HER-2) negative
• No clear decision on whether chemotherapy should be given as adjunct based on current prognostic criteria
• Consented to GEP testing
• Able to give full informed consent to IMPARTER study
• Good comprehension of the Italian language
• Access to internet connection and devices (e.g. smart phone, tablet, laptop or desktop computer)

You may not qualify if…

• Other breast cancer diagnosis (e.g. Ductal carcinoma in situ, Metastatic)
• Unable to give fully informed consent
• Under 18 years of age
• Unable to understand and speak Italian
• No access to internet connection or devices

Where it is running

• European Institute of Oncology — Milan, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.